MedTrace Logo

Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric Cancer

NCT01665274 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-10-03

No results posted yet for this study

Summary

The purpose of this study is to demonstrate that capecitabine/oxaliplatin as perioperative chemotherapy is superior or not to operation directly for locally advanced gastric cancer in terms of 3 year disease-free survival (DFS) rate.

Conditions

Interventions

DRUG

Capecitabine

Capecitabine 1,000 mg/m² twice daily, d1-14, q3w

DRUG

Oxaliplatin

Oxaliplatin IV infusion, 130mg/m² d1, q3w

PROCEDURE

D2 resection

D2 resection

Sponsors & Collaborators

  • Harbin Medical University

    lead OTHER

Principal Investigators

  • Yingwei Xue, Phd, MD · Harbin Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2020-08-31
Completion
2022-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01665274 on ClinicalTrials.gov